An era of regulatory compression for Quality Management

From our perspective, quality management is entering a period of unusual regulatory compression, in which multiple, long-anticipated changes are converging at once, leaving little room for incremental adaptation. For organizations operating in regulated industries (particularly life sciences and medical devices), the coming 18–24 months will require more than procedural updates. They will force a major rethink of how quality systems are designed, operated, and adopted.

The clearest signal of this shift is the FDA’s new Quality Management System Regulation (QMSR), which took effect on February 2, 2026. QMSR replaces the 30 year old Quality System Regulation (QSR) and incorporates ISO 13485:2016 as a reference. This is not a minor harmonization exercise. Every medical device manufacturer selling into the US market will be required to realign its quality system architecture to a framework that regulators already treat as a global baseline best practice.

At the same time, regulatory enforcement activity is accelerating. In fiscal year 2025, the FDA issued 303 warning letters to drug and biologics companies, roughly a 60% increase compared to FY2024. Device manufacturers saw a similar uptick, with 59 device-related warning letters issued in 2025 versus 45 the previous year. Unsurprisingly, CAPA deficiencies remain the most frequently cited category in Form 483 observations for devices.

These trends combined show us clearly that expectations are rising, tolerance for manual workarounds is shrinking, and the cost of running quality processes through disconnected SharePoint folders, Excel trackers, and email chains is increasing, both in terms of compliance risk and operational drag.

A global challenge, not a US-only problem

Regulatory change is happening in parallel across multiple jurisdictions.

In Europe, four EUDAMED modules become mandatory on May 28, 2026 for all new MDR and IVDR devices placed on the market, significantly increasing transparency obligations and data consistency requirements. The EU AI Act, which entered into force in August 2024, introduces new governance, risk management, and documentation expectations for AI enabled medical software, intersecting with existing quality and post market surveillance processes. Meanwhile, ISO 9001 is undergoing its first major revision in a decade, with a final standard expected in September 2026, impacting approximately 1.5 million certified organizations worldwide.

For companies selling globally, this creates a uniquely tensed operating environment. Quality leaders are being asked to navigate several evolving frameworks simultaneously, with overlapping but not identical requirements, using tools and processes that were never designed for such complexity or audit intensity.

The ever growing execution gap

Industry data reinforces what many quality teams already feel on the ground. Research from LNS Research (EQMS Solution Selection Matrix, 2025 Guidebook, LNS Research) shows that Quality Leaders are more than 60% more likely to deploy an enterprise-wide electronic Quality Management System (eQMS) than their lagging peers. Meanwhile, industrial and regulatory know-how within manufacturing environments is at an historic low due to workforce turnover and retirement.

The result is a widening execution gap: regulators expect consistent, closed-loop, data-driven quality processes, while many organizations still rely on systems that only specialist quality managers can realistically operate. Frontline adoption remains limited, audit preparation remains painful, and insight is retrospective rather than preventive.

That gap is precisely what is accelerating the shift from document-centric quality toward platform-based, workflow-driven eQMS solutions, especially those that prioritize usability and adoption, not just compliance on paper.

The BPA approach: usability, sovereignty, purpose-built

With BPA built natively on Microsoft 365, quality workflows live inside the digital environment that employees already use daily (email, Teams, SharePoint, Power Automate) rather than behind a separate login with its own training, governance, and change management burden. With more than 400 million paid commercial Microsoft 365 seats globally, this approach dramatically lowers the barrier to adoption.

Equally important is the data sovereignty model. Company’s data remains inside its own Microsoft tenant, under its existing security, retention, and compliance policies. For regulated industries and public-sector organizations, this is often a prerequisite. GCC High environments compatibility further reinforces BPA’s relevance for government and defence-related use cases.

Finally, BPA’s platforms (BPAQuality365 and BPAMedical365), reflect a balance between horizontal usability and vertical depth. While many generic platforms struggle to meet life sciences expectations without heavy configuration, BPAMedical365 delivers purpose-built functionality aligned with medical device and life sciences regulations from day one, without forcing organizations into rigid, proprietary ecosystems.

Modernize quality for resilience and scale

As the regulatory environment is not becoming simpler, fragmented, manual quality systems are no longer sufficient. Organizations that treat upcoming changes as an opportunity to modernize how quality actually operates across the enterprise will be far better off. Not just for audits, but for resilience and scale.

The compression is real. The question is whether quality systems will continue to lag behind or catch up.